After Phase III results, AZ's COPD combo heading for submissions

AstraZeneca plc (LSE:AZN; NYSE:AZN) said triple combination therapy PT010 met six of seven primary endpoints evaluating lung function in the Phase III KRONOS trial to treat moderate to very severe chronic obstructive pulmonary disease (COPD). AZ plans to submit regulatory applications for the fixed-dose combination next half in Japan and China and next year in the

Read the full 562 word article

How to gain access

Continue reading with a
two-week free trial.